A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer

Salminen, Liina; Nadeem, Nimrah; Jain, Shruti; Grénman, Seija; Carpén, Olli; Hietanen, Sakari; Oksa, Sinikka; Lamminmäki, Urpo; Pettersson, Kim; Gidwani, Kamlesh; Huhtinen, Kaisa; Hynninen, Johanna

doi:10.1016/j.ygyno.2019.12.025

Cited by 22 publications

(12 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CA-125 is a well-known biomarker, but its significance is still of interest to clinicians and researchers. Recently, the role of nadir CA-125 and its glycoforms have been assessed by Finnish authors 26 ; the results of their study may undermine the prognostic significance of nadir CA-125 26 . The impact of new therapies (PARP inhibitors, immunotherapy) on clinical significance of nadir CA-125 is unknown.…”

Section: Discussionmentioning

confidence: 99%

Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer

Piątek

Panek

Lewandowski

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The objective of this study was to evaluate the nadir CA-125 in patients with epithelial ovarian cancer. A total of 168 patients who achieved complete remission (no clinical and radiological signs, CA-125 ≤ 35 U/ml) after first-line treatment were enrolled in the study. The relationship between CA-125 and survival was examined by applying generalized additive models to the Cox proportional hazards model. The median CA-125 concentration after the treatment was 10 U/ml (2.7–35 U/ml). The nadir CA-125 was related to progression-free survival but not to overall survival. The risk of recurrence in patients with 11–25 U/ml and 26–35 U/ml compared to patients with ≤ 10 U/ml was 1.87 (p < 0.0024) and 2.17 (p < 0.018), respectively. An increased risk of recurrence according to the nadir CA-125 (≤ 10 U/ml vs. 11–25 U/ml and ≤ 10 U/ml vs. 26–35 U/ml) was found in patients with high-grade tumours (hazard ratio, HR = 2.08 and 2.59, respectively), advanced disease (HR = 2.38 and 2.03, respectively), serous histology (HR = 2.08 and 2.43, respectively) and after complete cytoreduction (HR = 2.7 and 2.72, respectively). No correlation between the CA-125 nadir and recurrence risk was found in patients with early-stage disease or those receiving neoadjuvant chemotherapy or bevacizumab.

show abstract

Section: Discussionmentioning

confidence: 99%

Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer

Piątek

Panek

Lewandowski

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…However, it is currently in use as an adjunct to diagnosis, in the monitoring of response to therapy, detection of recurrence of disease and determination of prognosis in EOC. Although a nonspecific marker of disease, it has been found to be elevated in 50% of women with early stage EOC and 80% of women with advanced disease [14][15][16][17].…”

Section: Discussionmentioning

confidence: 99%

The relationship between pre-operative lymphocyte to monocyte ratio and serum cancer antigen-125 among women with epithelial ovarian cancer in Lagos, Nigeria

Soibi-Harry¹,

Amaeshi²,

Garba³

et al. 2021

ecancer

View full text Add to dashboard Cite

Ovarian cancer (OC) is the second most common genital cancer worldwide, and the most lethal of all genital cancers. The role of inflammation and markers of systemic inflammation such as neutrophils, lymphocytes and monocytes in cancer biology have been investigated and reported in many studies. Cancer antigen 125 (CA-125) is currently in use as an adjunct to diagnosis, prognostication and monitoring of epithelial OC (EOC). This test is not readily available in many centres in sub-Saharan Africa, creating a need to identify alternative markers that are available and affordable. This study aimed to determine the relationship between pre-operative serum lymphocyte to monocyte ratio (LMR) and CA-125 in EOC. This was a retrospective cross-sectional study among 70 women, diagnosed with EOC in Lagos University Teaching Hospital from January 2013 to December 2019. Data were extracted from the case notes of the patients. LMR was calculated as the absolute lymphocyte count divided by the absolute monocyte count and analysed using Statistical Package for Social Sciences (SPSS) version 25.0. The correlation between LMR and CA-125 was determined using Pearson's correlation coefficient. The mean age of the patients was 48.57 ± 13.97 years. Serous adenocarcinoma was the most common subtype of EOC making up 94.3% of the cases. The median serum CA-125 was 393.5 (215.00-765.67) U/mL. The median LMR was 6.77 (1.28-43.0). There was a statistically significant negative correlation between CA-125 and LMR, r = −0.28, p = 0.02. LMR was negatively associated with CA-125 in women with EOC. LMR may be considered as a simple, affordable alternative marker to CA-125 in the management of EOC.

show abstract

“…7,8 CA 125 levels are often used to evaluate treatment response in patients diagnosed with epithelial ovarian cancer especially HGSC. 9,10 Previous studies have investigated the significance of CA 125 level at the time of diagnosis. [11][12][13] Those studies showed that CA 125 levels were predictive of survival among patients with epithelial ovarian cancer, but outcomes are still unclear.…”

Section: 5mentioning

confidence: 99%

Initial Ca 125 Value as a Predictive Marker for High-grade Serous Ovarian Cancer

2021

J Coll Physicians Surg Pak

View full text Add to dashboard Cite

show abstract

A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer

Abstract: is a more sensitive indicator of tumor load than conventional CA125. • The nadir value of CA125-STn is a predictor of progression free survival. • The CA125-STn assay detects relapse more precisely than the conventional CA125 assay.

Cited by 22 publications

References 35 publications

Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer

Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer

The relationship between pre-operative lymphocyte to monocyte ratio and serum cancer antigen-125 among women with epithelial ovarian cancer in Lagos, Nigeria

Initial Ca 125 Value as a Predictive Marker for High-grade Serous Ovarian Cancer

Contact Info

Product

Resources

About